Cu(I)-Catalyzed Diamination of Disubstituted Terminal Olefins: An Approach to Potent NK<sub>1</sub> Antagonist
作者:Yuehong Wen、Baoguo Zhao、Yian Shi
DOI:10.1021/ol900808z
日期:2009.6.4
This paper describes a diamination process using di-tert-butyldiaziridinone as nitrogen source and CuCl as catalyst. A wide variety of disubstituted terminalolefins can be efficiently diaminated in good yields under mild condition. This diamination process was used to synthesize potent NK1 antagonist Sch 425078.
本文描述了使用二叔丁基二氮杂环丙烷酮作为氮源和氯化铜作为催化剂的二胺化过程。多种二取代端烯烃可以在温和条件下以良好的产率有效地二胺化。这种二胺化过程用于合成有效的 NK 1拮抗剂Sch 425078。
作者:Federica Carlet、Greta Bertarini、Gianluigi Broggini、Alexandre Pradal、Giovanni Poli
DOI:10.1002/ejoc.202100026
日期:2021.4.22
An oxoammonium‐mediated α‐C(sp3) allylation of allyl‐ and benzyl ethers using allylsilanes as nucleophilic partners is disclosed. This new C−C bond forming C−H activation process allows to obtain the corresponding coupled products in moderate to good yields.
Regio- and stereoselective hydrostannation of allenes using dibutyliodotin hydride (Bu2SnIH) and successive coupling with aromatic halides
作者:Naoki Hayashi、Kazunao Kusano、Shingo Sekizawa、Ikuya Shibata、Makoto Yasuda、Akio Baba
DOI:10.1039/b712998j
日期:——
Regio- and stereoselective hydrostannation of allenes by using di-n-butyliodotin hydride (Bu2SnIH) was accomplished to give α,β-disubstituted vinyltins, which induced the synthesis of multi-substituted alkenes in a one-pot procedure.
Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I)
wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is
the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.
The present provides a condensed pyridine compound (I) represented by the following formula:
(wherein, R2 represents
ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and
B represents
its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.